Waldenstrom Macroglobulinemia: Clinical Presentation, Diagnosis, and Management in an Elderly Male
- PMID: 37750145
- PMCID: PMC10518236
- DOI: 10.7759/cureus.44127
Waldenstrom Macroglobulinemia: Clinical Presentation, Diagnosis, and Management in an Elderly Male
Abstract
Waldenstrom macroglobulinemia (WM) is a rare lymphoproliferative disease that can have an ambiguous clinical presentation. A key component of the pathophysiology of WM is bone marrow infiltration, which most commonly presents as anemia. Other symptoms of WM tend to be generalized and non-specific, which presents a diagnostic challenge. This was the case with our patient as well, when he presented to our outpatient clinic with non-specific symptoms. We present a 79-year-old male with longstanding pancytopenia, polyarthralgia, bilateral pedal edema, decreased appetite, and increased bleeding from wounds. The patient had a complete blood count (CBC) and complete metabolic panel (CMP) done, confirming present anemia, which prompted inpatient treatment and an oncology workup, confirming WM. The patient began a zanubrutinib monotherapy regimen, showing improvement in his pancytopenia, polyarthralgia, and overall symptoms.
Keywords: bone marrow aspirate; bruton tyrosine kinase inhibitor; cxcr4; hyperviscosity syndrome; kappa-lambda ratio; large b-cell lymphoma; monoclonal igm gammopathy; pancytopenia; waldenstrom; waldenstroms macroglobulinemia.
Copyright © 2023, Shahab et al.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures

Similar articles
-
Simple headache revealed a rare lymphoma: Waldenstrom macroglobulinemia with unique markers: a case report and review of the literature.J Egypt Natl Canc Inst. 2022 Mar 7;34(1):10. doi: 10.1186/s43046-022-00107-6. J Egypt Natl Canc Inst. 2022. PMID: 35253074 Review.
-
Coming of Age for BTK Inhibitor Therapy: A Review of Zanubrutinib in Waldenström Macroglobulinemia.Cells. 2022 Oct 19;11(20):3287. doi: 10.3390/cells11203287. Cells. 2022. PMID: 36291152 Free PMC article. Review.
-
Beyond monoclonal gammopathy of undetermined significance, clinical spectrum of immunoglobulin M gammopathy: a case series with focus on the diagnostic and management challenges.Int J Hematol Oncol. 2023 Feb 24;12(2):IJH44. doi: 10.2217/ijh-2022-0006. eCollection 2023 Jun. Int J Hematol Oncol. 2023. PMID: 37304326 Free PMC article.
-
Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia.Hematol Oncol. 2019 Apr;37(2):117-128. doi: 10.1002/hon.2539. Epub 2018 Sep 7. Hematol Oncol. 2019. PMID: 30192023 Review.
-
Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First.Ther Clin Risk Manag. 2022 Jun 23;18:657-668. doi: 10.2147/TCRM.S338655. eCollection 2022. Ther Clin Risk Manag. 2022. PMID: 35770040 Free PMC article. Review.
References
-
- Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the surveillance, epidemiology and end results database. Castillo JJ, Olszewski AJ, Kanan S, Meid K, Hunter ZR, Treon SP. Br J Haematol. 2015;169:81–89. - PubMed
Publication types
LinkOut - more resources
Full Text Sources